Vittorio Sebastiano, globally recognized for pioneering science, expands his role at company he co-founded as it moves closer to clinical research MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire/ Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that co-founder Vittorio Sebastiano, PhD, will become its head of research. Sebastiano led development of the unique mRNA-based ERA (Epigenetic Reprogramming of Aging) platform Turn Bio uses to produce tailored protein cocktails to rejuvenate targeted cells. He assumes his role as head of research this month. Sebastiano has served as chairman of Turn Bio's Scientific Advisory Board since he co-founded the company in 2018. A Stanford School of Medicine faculty member, author of more than 50 scientific articles and frequent speaker at research conferences around the world, Sebastiano is prominent in the emerging field of cellular reprogramming. His
CDC advisory committee approves racial considerations over lives saved
Two Ivy League medical professors are facing backlash for recommending that COVID-19 vaccine distribution should be prioritized based on skin color rather than risk level.
The University of Pennsylvania’s Harald Schmidt and Harvard University’s Marc Lipsitch have since somewhat walked back their comments to
The New York Times, though Lipsitch claimed his views were misinterpreted.
Neither the professors nor their academic institutions responded to
College Fix requests for comment on the medical scholars’ stated views that predominantly white groups should not get vaccine priority.
Schmidt and Lipsitch were discussing the Advisory Committee on Immunization Practices’ pending recommendations to the CDC on which group should get vaccines first, “essential workers” or elderly people.